RG
LGND icon

Renaissance Group’s Ligand Pharmaceuticals LGND Stock Holding History

Renaissance Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,982
Closed -$422K – 267
2018
Q4 		$422K Buy
4,982
+1,622
+48% +$173K 0.02% 220
2018
Q3 		$575K Buy
+3,360
New +$507K 0.02% 207

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return

Renaissance Group's LGND Position: Q1 2019 in Review

Renaissance Group sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 4,982 shares — an estimated $422K sold.

Renaissance Group first reported a position in LGND in Q3 2018 and held it in 2 quarters. The position peaked at $575K in Q3 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

  • Renaissance Group reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Renaissance Group sold 4,982 Ligand Pharmaceuticals shares in Q1 2019, an estimated $422K.
  • Renaissance Group first reported a position in Ligand Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Renaissance Group's Ligand Pharmaceuticals position peaked at $575K in Q3 2018.
  • 330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Renaissance Group's 13F filing for Q1 2019, filed 30 Apr 2019.